Researchers at ETH Zurich combined two CRISPR-Cas methods to decipher how mutations in a cell’s genome affect its function.
University of Wisconsin–Madison researchers targeting a group of hereditary neurodegenerative diseases have found success ...
The agency’s ability to hire and retain skilled employees may be in jeopardy given Trump ally Robert F. Kennedy Jr.’s ...
ETH Zurich researchers used combined CRISPR techniques to reveal unknown cancer-related mutations in the EGFR gene, ...
University of Wisconsin-Madison researchers targeting a group of hereditary neurodegenerative diseases have found success ...
Research reveals SLC13A3's role in tumor cell survival and immune therapy resistance, highlighting its potential as a target ...
In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...
In recent years, scientists have created a range of new methods based on CRISPR-Cas technology for precisely editing the ...
Repare Therapeutics Inc. ("Repare" or the "Company") , a leading clinical-stage precision oncology company, today announced a Cooperative Research and Development Agreement (CRADA) has been executed ...
Scientists at Vilnius University have developed a novel gene silencing method using a type IV-A CRISPR system that silences ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback